Showing results (21-30 of 302) with videos related to
Sort By:
Pageof 31
Journal of the American Academy of Dermatology|July 2, 2003
Ulcerated epithelioid hemangioendothelioma of the foot in childhoodAndrea Forschner, Dieter Harms, Gisela Metzler, et al.Expert Opinion on Investigational Drugs|October 15, 2010
PLX4032: does it keep its promise for metastatic melanoma treatment?Elisabeth Livingstone, Lisa Zimmer, Sarah Piel, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 11, 2012
Side effects of systemic oncological therapies in dermatologyLisa Zimmer, Julia Vaubel, Elisabeth Livingstone, et al.Cancers|January 21, 2022
Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic MelanomaMarcus Wölffer, Florian Battke, Martin Schulze, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 1, 2007
[G-DRG version 2007: a short overview]Marcel L Müller, Andrea Forschner, Thomas A Luger, et al.Melanoma Research|March 11, 2010
Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?Ulrike Leiter, Petra G Buettner, Thomas K Eigentler, et al.Cancers|October 28, 2023
Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative StudyManuel Kolb, Andrea Forschner, Christoph Artzner, et al.Journal of Cancer Research and Clinical Oncology|January 18, 2024
Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017Markus Reitmajer, Ulrike Leiter, Lena Nanz, et al.European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitorsTheresa Ruf, Rafaela Kramer, Andrea Forschner, et al.Current Oncology Reports|April 2, 2023
The Latest Option: Nivolumab and Relatlimab in Advanced MelanomaLea Jessica Albrecht, Elisabeth Livingstone, Lisa Zimmer, et al.Pageof 31